New warnings added to controversial antibiotic
Sanofi-Aventis has added new warnings to its antibiotic Ketek after talks with the FDA. The drug company says the warnings are intended to update doctors and patients on potential adverse events. But the warning is unlikely to quell the controversy around the drug, which has been linked to 12 cases of liver damage. Sanofi-Aventis says the rewards still outweigh any risks associated with Ketek.
- read the AFX report on Ketek
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
